Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

November 8, 2024

Study Completion Date

November 8, 2024

Conditions

Mesenchymal Stromal CellsCorneaCorneal DefectCorneal Epithelium Defect

Interventions

BIOLOGICAL

MSC Secretome Eye Drops

MSC Secretome eye drop will be dispensed.

Trial Locations (1)

University of Illinois at Chicago, Chicago

All Listed Sponsors

collaborator

National Eye Institute (NEI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Illinois at Chicago

OTHER

NCT05204329 - Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease | Biotech Hunter | Biotech Hunter